Style | Citing Format |
---|---|
MLA | Kolivand S, et al.. "Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain." Human Antibodies, vol. 28, no. 2, 2020, pp. 131-139. |
APA | Kolivand S, Nazari M, Modarressi MH, Najafabadi MRH, Hemati A, Ghafourifard S, Motevaseli E (2020). Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain. Human Antibodies, 28(2), 131-139. |
Chicago | Kolivand S, Nazari M, Modarressi MH, Najafabadi MRH, Hemati A, Ghafourifard S, Motevaseli E. "Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain." Human Antibodies 28, no. 2 (2020): 131-139. |
Harvard | Kolivand S et al. (2020) 'Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain', Human Antibodies, 28(2), pp. 131-139. |
Vancouver | Kolivand S, Nazari M, Modarressi MH, Najafabadi MRH, Hemati A, Ghafourifard S, et al.. Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain. Human Antibodies. 2020;28(2):131-139. |
BibTex | @article{ author = {Kolivand S and Nazari M and Modarressi MH and Najafabadi MRH and Hemati A and Ghafourifard S and Motevaseli E}, title = {Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain}, journal = {Human Antibodies}, volume = {28}, number = {2}, pages = {131-139}, year = {2020} } |
RIS | TY - JOUR AU - Kolivand S AU - Nazari M AU - Modarressi MH AU - Najafabadi MRH AU - Hemati A AU - Ghafourifard S AU - Motevaseli E TI - Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain JO - Human Antibodies VL - 28 IS - 2 SP - 131 EP - 139 PY - 2020 ER - |